· News · News Desk
PBS, ProPublica, and Allure all advanced the FDA's summer review of BPC-157 and six other restricted peptides. TODAY ran a mainstream feature on emotional blunting on GLP-1s, and CBC confirmed generic semaglutide on Canadian pharmacy shelves. Plus: Nature Methods on zero-shot peptide sequencing and a new oral GLP-1 delivery system that drops the fasting requirement.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.